| 0.2949 Data as of 10:59am ET |  -0.0051 / -1.70%Today’s Change | 0.17 Today|||52-Week Range 0.72 | -41.02% Year-to-Date |
| SECTOR Finance | INDUSTRY Finance/Rental/Leasing | MARKET CAP $9.6M |
Company Description
Omni Bio Pharmaceutical, Inc. is a development stage biopharmaceutical company which acquires, licenses, and develops existing therapies for indications with substantial commercialization potential. The company currently focuses on Alpha-1 Antitrypsin and on developing new recombinant versions that can be applied to the treatment of a range of inflammatory and immune diseases, including Type 1 diabetes, complications due to bone marrow transplantation referred to as graft versus host disease, acute myocardial infarction, and inflammatory bowel disease. It was founded on December 1, 2005 and is headquartered in Greenwood Village, CO.
Employees
Shareholders
| Individual stakeholders | 25.21% |
| Mutual fund holders | -- |
| Other institutional | -- |
Top Executives
| Bruce E. Schneider, PhD | Chief Executive Officer & Director |
| Robert Cecil Ogden, CPA | CFO, Secretary, Treasure & Head-Investor Relations |
| Charles A. Dinarello, MD | CSO & Director-Medical Affairs |
.
